You are here: Home

GSK

Accelerating the Benefits Achievable from Biocatalysis
02.10.2014

Accelerating the Benefits Achievable from Biocatalysis

Recently, Codexis has signed a platform technology license agreement with GlaxoSmithKline (GSK). Under the terms of the agreement, Codexis, a developer of biocatalysts for the pharmaceutical and fine chemical industries, granted GSK a license to use the company's proprietary CodeEvolver protein engineering platform technology in the field of human healthcare. more
23.09.2014

China Fines GSK Nearly $500 Million on Bribery Charges

GlaxoSmithkline (GSK), the UK's largest pharmaceutical producer, will pay the Chinese government nearly $500 million in fines after being found guilty of offering bribes to healthcare workers. Acknowledging that its local management had broken the law and also violated company rules, GSK has apologized to Chinese patients, doctors and hospitals and to the Chinese government. more
29.08.2014

GSK’s Ebola Vaccine Fast-tracked Into Clinical Trials

An experimental Ebola vaccine from GlaxoSmithKline is being fast-tracked into clinical trials with human patients, and the company plans to immediately begin building a stockpile of up to 10,000 doses for emergency deployment if results are good. more
Gordon Sangster to Join Codexis as Senior Vice President & CFO
29.07.2014

Gordon Sangster to Join Codexis as Senior Vice President & CFO

Codexis, a developer of biocatalysts for the pharmaceutical and fine chemical industries, announced that Gordon Sangster has agreed to join Codexis as Senior Vice President & Chief Financial Officer. Gordon, who will start on August 18, 2014, will manage all aspects of Codexis' financial and accounting functions and will report to John Nicols, President & Chief Executive Officer. more
28.07.2014

New Corruption Allegations Against GSK From Syria

Allegations of corruption continue to dog British pharmaceutical company GlaxoSmithKline (GSK). The latest reports come from Syria, where the drugmaker and its distributor have been accused of paying bribes to secure business, according to a whistleblower's email reviewed by the news agency Reuters. more
18.07.2014

Codexis Enters into Technology Collaboration with GSK

Codexis, a developer of biocatalysts for the pharmaceutical and fine chemical industries headquartered in Redwood City, Calif./USA, has signed a platform technology license agreement with GlaxoSmithKline (GSK). more
16.07.2014

Glaxo-Linked Foreign Investigators Said Indicted

Prosecutors in Shanghai have indicted Peter Humphrey, a 58-year-old UK citizen, and Yu Yingzeng, a 61-year-old US citizen, for illegally obtaining personal information on Chinese citizens, the official Chinese news agency Xinhua reports. It is the first indictment Chinese prosecutors have announced of foreigners for conducting an illegal investigation, according to Xinhua. The agency said local courts will hear the case of the two investigators at an unspecified date. more
02.07.2014

Sex Video is New Twist in GSK China Bribery Scandal

GlaxoSmithKline (GSK) has confirmed the existence of an intimate video recording of its former China head, Mark Reilly, which the London-based Sunday Times reported kicked off a bribery investigation that has damaged the pharmaceutical giant's business in China. The newspaper said the recording was shot without Reilly's knowledge or consent at his Shanghai flat and showed the Briton, who is separated from his wife, with his Chinese girlfriend. more
30.05.2014

GSK Invites Private Equity Bids for Older Drugs

UK pharmaceutical producer GlaxoSmithKline has invited private equity firms to consider making offers for a range of its older drugs, news agencies report, citing people familiar with the matter. more
19.05.2014

Corruption Charges Against GSK Seen as Warning

Corruption charges against representatives of UK drugmaker GlaxoSmithKline (GSK) in China are a warning to other foreign firms and could do irreparable damage to the company's Chinese operations, the official Xinhua news agency said. Chinese police charged GSK's legal representative in China, Mark Reilly, and two others with corruption after a 10-month probe found that the firm made billions of yuan from bribing doctors and hospitals. more
RSS Newsletter